Obexelimab for the Treatment of IgG4-Related Disease.

Obexelimab significantly prolongs time to disease flare and reduces glucocorticoid exposure in patients with IgG4-related disease.

• Why it matters: IgG4-related disease affects multiple organs and often relapses after glucocorticoid therapy, which has toxic effects, highlighting the need for safer, more effective treatments.
• What they did: A phase 3, double-blind, randomized, placebo-controlled trial enrolled 194 patients who received weekly subcutaneous obexelimab or placebo for 52 weeks, with glucocorticoids tapered to discontinuation by week 8.
• The result: Obexelimab significantly delayed disease flares (hazard ratio, 0.44; P<0.001), increased complete remission (37.1% vs. 19.6%; P=0.005), and decreased glucocorticoid rescue dose (329.5 mg vs. 929.8 mg; P=0.004), with fewer serious adverse events than placebo.